Apixaban in Obese Patients

Please use landscape view or desktop screen to view the content.

Pre-IPTW and Post-IPTW Baseline Characteristics Among Obese* Patients With NVAF Initiating Apixaban Versus Warfarin¹

Deitelzweig VA and Medicare 2022

	Pre-IPTW			Post-IPTW^‡
	Warfarin cohort (ref)	Apixaban cohort	STD^†	Warfarin cohort (ref)	Apixaban cohort	STD^†
Sample size	12,918	13,604		12,918	13,604
US geographic region, n (%)
Northeast	2462 (19)	2413 (18)	3.4	2364 (18)	2487 (18)	0.1
Midwest	4118 (32)	3748 (28)	9.5	3837 (30)	4039 (30)	0.0
South	4270 (33)	5289 (39)	12.2	4654 (36)	4900 (36)	0.0
West	2037 (16)	2103 (16)	0.9	2021 (16)	2135 (16)	0.1
Other/Unknown	31 (0)	51 (0)	2.4	41 (0)	43 (0)	0.0
*Body weight (kg),** mean (SD)	111.5 (19.4)	109.5 (16.8)	11.2	111.0 (19.1)	109.9 (17)	6.2
*BMI (kg/m²),** mean (SD)	37.1 (63.5)	35.4 (36.3)	3.2	37.2 (69.5)	35.5 (33.3)	3.2
CCI, mean (SD)	3.1 (2.6)	2.6 (2.4)	20.3	2.8 (2.5)	2.9 (2.6)	0.5
CHA₂DS₂-VASc score	3.8 (1.6)	3.8 (1.5)	5.3	3.8 (1.5)	3.8 (1.5)	1.5
HAS-BLED score^§	2.7 (1.1)	2.6 (1.1)	5.5	2.7 (1.1)	2.6 (1.1)	5.5
Dose of index OAC prescription, n (%)
Standard dose (apixaban 5 mg)	---	11,813 (87)	---	---	11,890 (87)	---
Low dose (apixaban 2.5 mg)	---	1791 (13)	---	---	1714 (13)	---

1|2|3

*Obesity was defined as BMI ≥30 kg/m² or body weight ≥100 kg within ±6 months of the index date. The value closest to the index date was chosen. ^†STD = 100 × (actual STD). STD >10 was considered significant.
^‡After applying weights, the values for the baseline variables were not whole numbers; therefore, due to rounding, the sum of patients may not equal 100%.
^§As the international INR was not available in the databases, a modified HAS-BLED score was calculated with a range of 0 to 8.

BMI, body mass index; CCI, Deyo-Charlson Comorbidity Index; CHA₂DS₂-VASc, congestive heart failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65 to 74 and sex category (female); HAS-BLED, hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly; INR, international normalized ratio; IPTW, inverse probability treatment weighting; NVAF, nonvalvular atrial fibrillation; OAC, oral anticoagulant; ref, reference; SD, standard deviation; STD, standardized difference.

Pre-IPTW and Post-IPTW Baseline Characteristics Among Obese* Patients With NVAF Initiating Apixaban Versus Warfarin1

Pre-IPTW and Post-IPTW Baseline Characteristics Among Obese* Patients With NVAF Initiating Apixaban Versus Warfarin¹